Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

BACKGROUND: Imatinib inhibits the KIT and PDGFR tyrosine kinases, resulting in its notable antitumor activity in gastrointestinal stromal tumor (GIST). We previously reported the early results of a multi-institutional prospective trial (RTOG 0132) using neoadjuvant/adjuvant imatinib either in primar...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Wang, Dian, Zhang, Qiang, Blanke, Charles D., Demetri, George D., Heinrich, Michael C., Watson, James C., Hoffman, John P., Okuno, Scott, Kane, John M., von Mehren, Margaret, Eisenberg, Burton L.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3800166/
https://ncbi.nlm.nih.gov/pubmed/22203182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-011-2190-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares